Updates are available Correction dated 2020-06-13

Article History

Received: 23 June 2019

Accepted: 24 September 2019

First Online: 9 November 2019

Change Date: 13 June 2020

Change Type: Correction

Change Details: Missing Electronic Supplementary Materials.

Compliance with ethical standards

:

: H.M.W. Verheul is member of the advisory board of Erbitux (Merck); he has also received honoraria from Boehringer Ingelheim and Roche for his consultancy work. H.M.W. Verheul received research funding from Amgen, Vitromics Healthcare, Immunovo BV, Roche, and Novartis. C.W. Menke-van der Houven van Oordt is a member of the advisory board G1 and Novartis; she also received research grants from Crystal Therapeutics, BMS, and G1. E.G.E. de Vries reports Institutional Financial Support for her advisory role from Daiichi Sankyo, Merck, NSABP, Pfizer, Sanofi, and Synthon and Institutional Financial Support for clinical trials or contracted research from Amgen, AstraZeneca, Bayer, Chugai Pharma, CytomX Therapeutics, G1 Therapeutics, Genentech, Nordic Nanovector, Radius Health, Regeneron, Roche, and Synthon, all outside the submitted work. There are no conflicts of interests for all others.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

: The funder had no role in study design, data collection and analysis, or preparation of the manuscript.